In this study, we reported, for first time, that FGF21 plays a critical role for negative feedback on the hepatocyte-derived IL-17A production to attenuate NASH development and NASH-HCC transition. The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatohepatitis.